Eagle Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$14.7M
Doctors Paid
4,867
Transactions
6,908
2024 Total
$177,062
Payment Breakdown by Category
Research$13.5M (92.1%)
Consulting$258,781 (1.8%)
Food & Beverage$238,336 (1.6%)
Travel$115,432 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $13.5M | 211 | 92.1% |
| Honoraria | $368,903 | 125 | 2.5% |
| Consulting Fee | $258,781 | 95 | 1.8% |
| Food and Beverage | $238,336 | 6,174 | 1.6% |
| Charitable Contribution | $160,342 | 21 | 1.1% |
| Travel and Lodging | $115,432 | 277 | 0.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $21,608 | 5 | 0.1% |
Payments by Type
Research
$13.5M
211 transactions
General
$1.2M
6,697 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A PHASE 1, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLDERABILITY, AND PHARMACOKINETICS OF FULVESTRANT TEST VS. REFERENCE FOLLOWING INTRAMUSCULAR ADMINISTRATION TO THE GLUTEAL MUSCLE IN HEALTHY FEMALE SUBJECTS, PROTOCOL NO. EGL-5 | $9.1M | 0 | 131 |
| STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF FULVESTRANT AFTER IM ADMINISTRATION | $1.9M | 0 | 30 |
| PHASE 1, RANDOMIZED, OPEN-LABEL, SINGLE-CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETCS OF THREE FORMULATIONS OF FULVESTRANT FOR INJECTABLE SUSPENSION TEST COMPARED TO FASLODEX INJECTION REFERENCE FOLLOWING SINGLE DOSE INTRAMUSCU | $1.7M | 0 | 8 |
| TO ASSESS THE POTENTIAL NEUROPROTECTIVE EFFECTS AND SAFETY OF INTRANASAL ADMINISTRATION OF DANTROLENE IN A 5XFAD ALZHEIMER S DISEASE MOUSE MODEL. | $277,170 | 0 | 5 |
| INVESTIGATION OF REMIMAZOLAM IN CHILDREN UNDERGOING SEDATION FOR MEDICAL PROCEDURES | $202,847 | 0 | 10 |
| EAGL11.5860 Bendamustine HCL BDM | $64,808 | 0 | 12 |
| A PILOT TRIAL TO DEMONSTRATE THE FEASIBILITY OF USING DANTROLENE TO STUDY RYR2 INHIBITION TO PREVENT VENTRIBULAR ARRHYTHMIAS - AHA STRATEGICALLY FOCUSED RESEARCH NETWORK | $59,655 | 0 | 1 |
| STUDY IS TO EVALUATE RYANODEX AS A TREATMENT FOR TRAUMATIC BRAIN INJURY TBI IN A RODENT TBI MODEL | $56,400 | 0 | 2 |
| EVALUATION OF THE EFFICACY OF RYANODEX AS A TREATMENT FOR TRAUMATIC BRAIN INJURY IN A RODENT MODEL | $44,454 | 0 | 1 |
| MULTI-ARM OPTIMIZATION OF STROKE THROMBOLYSIS MOST | $36,000 | 0 | 1 |
| ACADEMIC STUDY | $32,539 | 0 | 2 |
| EAGL11.5860 Bendamustine HCL (BDM) | $12,812 | 0 | 6 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2019 |
|---|---|---|---|---|
| Dr. Julian Bailes, Md, MD | Neurological Surgery | Evanston, IL | $123,491 | $0 |
| Dr. Randall Ostroff, Md, MD | Anesthesiology | Berwyn, IL | $59,024 | $0 |
| Kevin Henson, Crna, CRNA | Nurse Anesthetist, Certified Registered | Indianapolis, IN | $52,101 | $0 |
| James Glazer, Md, MD | Family Medicine | North Conway, NH | $47,820 | $0 |
| Ronak Desai, Do, DO | Anesthesiology | Camden, NJ | $40,298 | $0 |
| Tong Gan, M.d, M.D | Anesthesiology | Houston, TX | $32,644 | $0 |
| Erik Rauch, Crna, CRNA | Nurse Anesthetist, Certified Registered | St Petersburg, FL | $30,806 | $0 |
| Louis Guzzi, Md, MD | Critical Care Medicine | Orlando, FL | $30,072 | $0 |
| Dr. David Leiman, M.d, M.D | Anesthesiology | Houston, TX | $27,247 | $0 |
| Dr. Usama Hamdan, M.d, M.D | Facial Plastic Surgery | Westwood, MA | $24,742 | $0 |
| James Williams, D.o, D.O | Emergency Medicine | San Antonio, TX | $20,963 | $0 |
| Sabry Ayad, M.d, M.D | Anesthesiology | Cleveland, OH | $20,552 | $0 |
| Dr. John Capacchione, M.d, M.D | Anesthesiology | Apo, AE | $20,479 | $0 |
| Dr. John Erkmann, D.o, D.O | Pediatric Anesthesiology | Kansas City, MO | $16,294 | $0 |
| Ara Klijian, M.d, M.D | Thoracic Surgery (Cardiothoracic Vascular Surgery) | San Diego, CA | $15,814 | $0 |
| Jonathan Riddle, Crna, CRNA | Nurse Anesthetist, Certified Registered | Ft Worth, TX | $15,720 | $0 |
| Mr. George Gregory, M.d, M.D | Anesthesiology | San Francisco, CA | $15,644 | $0 |
| Matt Friedman, Md, MD | Emergency Medicine | New York, NY | $13,728 | $0 |
| Dr. William Hampton, D.o, D.O | Emergency Medicine | Shawano, WI | $12,888 | $0 |
| Dr. Michael Lew, Md, MD | Anesthesiology | Duarte, CA | $12,309 | $0 |
| Dr. Asa Margolis, Do, Mph, Ms, DO, MPH, MS | Emergency Medicine | Baltimore, MD | $12,246 | $0 |
| Dr. Wayne Reichman, M.d, M.D | Vascular Surgery | Glen Arm, MD | $10,846 | $0 |
| Jeannette Kierce, Md, MD | Anesthesiology | Richmond, VA | $10,638 | $0 |
| Dr. Richard Dutton, M.d, M.D | Anesthesiology | Dallas, TX | $8,200 | $0 |
| Nathan Gilmore, Md, MD | Emergency Medical Services | Dana Point, CA | $8,176 | $0 |
Ad
Top Products
- NOVEL FULVESTRANT FORMULATION $1.9M
- Fulvestrant $1.7M
Associated Products (7)
- NOVEL FULVESTRANT FORMULATION $1.9M
- Fulvestrant $1.7M
- Ryanodex $625,640
- Ryanodex Single Use Only - 250ml $276,492
- Bendamustine HCL $77,620
- Argatroban 1 vial in one carton $36,000
- PEMFEXY $25,827
Payment Categories
- Food & Beverage $238,336
- Consulting $258,781
- Travel & Lodging $115,432
- Research $13.5M
About Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals, Inc. has made $14.7M in payments to 4,867 healthcare providers, recorded across 6,908 transactions in the CMS Open Payments database. In 2024, the company paid $177,062. The top product by payment volume is NOVEL FULVESTRANT FORMULATION ($1.9M).
Payments were distributed across 124 medical specialties. The top specialty by payment amount is Anesthesiology ($400,993 to 1,395 doctors).
Payment categories include: Food & Beverage ($238,336), Consulting ($258,781), Research ($13.5M), Travel & Lodging ($115,432).
Eagle Pharmaceuticals, Inc. is associated with 7 products in the CMS Open Payments database, including NOVEL FULVESTRANT FORMULATION, Fulvestrant, and Ryanodex.